JP2008533102A - 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 - Google Patents
平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 Download PDFInfo
- Publication number
- JP2008533102A JP2008533102A JP2008501329A JP2008501329A JP2008533102A JP 2008533102 A JP2008533102 A JP 2008533102A JP 2008501329 A JP2008501329 A JP 2008501329A JP 2008501329 A JP2008501329 A JP 2008501329A JP 2008533102 A JP2008533102 A JP 2008533102A
- Authority
- JP
- Japan
- Prior art keywords
- leucine
- acetyl
- unilateral
- nerve
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000669 acetylleucine Drugs 0.000 title claims abstract description 32
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 238000011282 treatment Methods 0.000 title description 11
- 208000012639 Balance disease Diseases 0.000 title description 2
- 208000027601 Inner ear disease Diseases 0.000 claims abstract description 16
- 208000027491 vestibular disease Diseases 0.000 claims abstract description 16
- 230000001154 acute effect Effects 0.000 claims abstract description 15
- 206010029864 nystagmus Diseases 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims abstract description 7
- 210000005036 nerve Anatomy 0.000 claims description 21
- 208000011580 syndromic disease Diseases 0.000 claims description 17
- 208000002173 dizziness Diseases 0.000 claims description 12
- 210000000860 cochlear nerve Anatomy 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000002271 resection Methods 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000036540 impulse transmission Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims 1
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 230000001720 vestibular Effects 0.000 description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010304 firing Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000003273 vestibular nerve Anatomy 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 230000012043 vestibular reflex Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001614 effect on membrane Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000010291 membrane polarization Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 230000009023 proprioceptive sensation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000024042 response to gravity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002480 semicircular canal Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0502696A FR2883180B1 (fr) | 2005-03-18 | 2005-03-18 | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| PCT/EP2006/060841 WO2006097527A1 (fr) | 2005-03-18 | 2006-03-17 | Utilisation de l'acétyl-leucine pour la préparation d'un médicament destiné au traitement de troubles de l'équilibre |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013081360A Division JP2013173759A (ja) | 2005-03-18 | 2013-04-09 | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533102A true JP2008533102A (ja) | 2008-08-21 |
| JP2008533102A5 JP2008533102A5 (https=) | 2009-04-30 |
Family
ID=35134794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501329A Pending JP2008533102A (ja) | 2005-03-18 | 2006-03-17 | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 |
| JP2013081360A Pending JP2013173759A (ja) | 2005-03-18 | 2013-04-09 | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013081360A Pending JP2013173759A (ja) | 2005-03-18 | 2013-04-09 | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080108702A1 (https=) |
| EP (1) | EP1865943A1 (https=) |
| JP (2) | JP2008533102A (https=) |
| CA (1) | CA2601101A1 (https=) |
| FR (1) | FR2883180B1 (https=) |
| WO (1) | WO2006097527A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013527222A (ja) * | 2010-06-03 | 2013-06-27 | ラオフ・レキク | 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン |
| US12433862B2 (en) | 2016-08-11 | 2025-10-07 | Intrabio Limited | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526408A (ja) * | 1998-10-02 | 2002-08-20 | ノバルティス アクチエンゲゼルシャフト | 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3455638B2 (ja) * | 1996-02-23 | 2003-10-14 | 株式会社モリタ製作所 | 平衡機能検査装置 |
| FR2749512B1 (fr) * | 1996-06-10 | 1999-08-13 | Pf Medicament | Utilisation de l'acetyl dl leucine pour le traitement des tremblements |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
-
2005
- 2005-03-18 FR FR0502696A patent/FR2883180B1/fr not_active Expired - Lifetime
-
2006
- 2006-03-17 CA CA002601101A patent/CA2601101A1/fr not_active Abandoned
- 2006-03-17 WO PCT/EP2006/060841 patent/WO2006097527A1/fr not_active Ceased
- 2006-03-17 US US11/886,419 patent/US20080108702A1/en not_active Abandoned
- 2006-03-17 JP JP2008501329A patent/JP2008533102A/ja active Pending
- 2006-03-17 EP EP06725137A patent/EP1865943A1/fr not_active Withdrawn
-
2013
- 2013-04-09 JP JP2013081360A patent/JP2013173759A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526408A (ja) * | 1998-10-02 | 2002-08-20 | ノバルティス アクチエンゲゼルシャフト | 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012006248; Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｓｃｉｅｎｃｅ Ｖｏｌ．１３, 2001, ｐ．７３５-７４８ * |
| JPN7012000451; Ｃｈｉｎｅｓｅ Ｊｏｕｒｎａｌ ｏｆ Ａｐｐｌｉｅｄ Ｐｈｙｓｉｏｌｏｇｙ Ｖｏｌ．１３， Ｎｏ．３, 1997, ｐ．２５７-２６０ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013527222A (ja) * | 2010-06-03 | 2013-06-27 | ラオフ・レキク | 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン |
| US12433862B2 (en) | 2016-08-11 | 2025-10-07 | Intrabio Limited | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| US12433863B2 (en) | 2016-08-11 | 2025-10-07 | Intrabio Limited | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1865943A1 (fr) | 2007-12-19 |
| FR2883180B1 (fr) | 2007-05-25 |
| WO2006097527A1 (fr) | 2006-09-21 |
| CA2601101A1 (fr) | 2006-09-21 |
| FR2883180A1 (fr) | 2006-09-22 |
| JP2013173759A (ja) | 2013-09-05 |
| US20080108702A1 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bae et al. | Current diagnosis and treatment of vestibular neuritis: a narrative review | |
| Motin et al. | Benign paroxysmal positional vertigo as the cause of dizziness in patients after severe traumatic brain injury: diagnosis and treatment | |
| Brandt et al. | Vertigo and dizziness: common complaints | |
| Hornibrook | Benign paroxysmal positional vertigo (BPPV): history, pathophysiology, office treatment and future directions | |
| Gray | Extra labyrinthine vertigo due to cervical muscle lesions | |
| Marcelli et al. | Neuro-otological features of benign paroxysmal vertigo and benign paroxysmal positioning vertigo in children: a follow-up study | |
| ES2295331T3 (es) | Agonistas de receptor nicotinico para el tratamiento de enfermedades inflamatorias pulmonares. | |
| US20230115611A1 (en) | Treatment of pain and vasoconstriction | |
| Young et al. | Disorders of the inner-ear balance organs and their pathways | |
| KR20120050473A (ko) | 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 | |
| Radtke et al. | Vestibulo-autonomic control in man: Short-and long-latency vestibular effects on cardiovascular function | |
| Cass et al. | Patterns of vestibular function following vestibular nerve section | |
| JP2013173759A (ja) | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 | |
| Oosterveld | The effectiveness of piracetam in vertigo | |
| El-Hashim et al. | Effect of a novel NK1 receptor selective antagonist (NKP608) on citric acid induced cough and airway obstruction | |
| EP2744497B1 (en) | Therapeutic combinations of netupitant and palonosetron | |
| TW202408474A (zh) | 疼痛抑制劑 | |
| JP2016523866A (ja) | 慢性外傷性脳障害ｉを予防及び／又は治療する方法 | |
| JP5366807B2 (ja) | Ｔ細胞のＴｈ１細胞への分化抑制剤 | |
| Drozd | Acute vertigo: peripheral versus central etiology | |
| HALMAGYI et al. | Vertigo and imbalance | |
| Grobbelaar | Vertigo-a practical approach | |
| Winston et al. | LVIII The Effects of Dramamine upon Cochlear Function and the Vestibular Responses to Turning in Normal Subjects | |
| JP2023042650A (ja) | 眼科用剤 | |
| Threja et al. | Impact of innate immune activation on T cell dynamics and functional recovery following traumatic brain injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120511 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120612 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120619 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120712 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121009 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130208 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130306 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130313 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130514 |